Why the study?
Do GPIbalpha inhibitors, P2Y1/P2Y12 antagonists, and aspirin reduce platelet thrombus formation induced by human atherosclerotic plaques under arterial flow?
Population
Human atherosclerotic plaques obtained by surgical endarterectomy exposed to hirudinized platelet-rich…
Comparison
Aspirin, P2Y1 antagonist MRS2179, P2Y12… vs Uninhibited state
Design
Preclinical
Authors
Loading...
Hypothesis-generating for GPIbα blockade in atherothrombosis; leaves open translation to human arterial disease.
Do GPIbalpha inhibitors, P2Y1/P2Y12 antagonists, and aspirin reduce platelet thrombus formation induced by human atherosclerotic plaques under arterial flow?
GPIbalpha inhibition and ADP receptor antagonists, but not aspirin, effectively reduce human plaque-induced platelet thrombus formation under arterial flow conditions.
Penz et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: